中国克罗恩病并发肠瘘诊治的专家共识意见

2018-12-30 中国医师协会外科医师分会 中华胃肠外科杂志.2018, 21(12):1337-1346.

克罗恩病是累及消化道全层的慢性炎性疾病,肠瘘是其最为严重的外科并发症。治疗目标是治愈肠瘘与腹腔感染、恢复消化道的连续性、减少术后复发和改善生活质量。临床上应对克罗恩病并发的肠瘘进行充分评估,努力促进肠瘘的自行愈合,联合肠内营养与外科引流有助于促进肠瘘自行愈合。同时要重视围手术期营养状况的评估,并给予营养支持治疗。合并的腹腔脓肿建议使用Trocar穿刺置双套管建立主动冲洗引流.药物、营养治疗以及外科

中文标题:

中国克罗恩病并发肠瘘诊治的专家共识意见

发布日期:

2018-12-30

简要介绍:

克罗恩病是累及消化道全层的慢性炎性疾病,肠瘘是其最为严重的外科并发症。治疗目标是治愈肠瘘与腹腔感染、恢复消化道的连续性、减少术后复发和改善生活质量。临床上应对克罗恩病并发的肠瘘进行充分评估,努力促进肠瘘的自行愈合,联合肠内营养与外科引流有助于促进肠瘘自行愈合。同时要重视围手术期营养状况的评估,并给予营养支持治疗。合并的腹腔脓肿建议使用Trocar穿刺置双套管建立主动冲洗引流.药物、营养治疗以及外科引流未能治愈的克罗恩病并发的肠外瘘与肠内瘘,需要考虑手术治疗,推荐腹腔镜手术应用于粘连较轻的克罗恩病并发的肠瘘,术后予以药物治疗并定期复查,尽可能减少克罗恩病术后复发以及肠瘘的再发。 

拓展指南:克罗恩病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=中国克罗恩病并发肠瘘诊治的专家共识意见)] GetToolGuiderByIdResponse(projectId=1, id=c9ae91c0016915ab, title=中国克罗恩病并发肠瘘诊治的专家共识意见, enTitle=, guiderFrom=中华胃肠外科杂志.2018, 21(12):1337-1346., authorId=null, author=, summary=克罗恩病是累及消化道全层的慢性炎性疾病,肠瘘是其最为严重的外科并发症。治疗目标是治愈肠瘘与腹腔感染、恢复消化道的连续性、减少术后复发和改善生活质量。临床上应对克罗恩病并发的肠瘘进行充分评估,努力促进肠瘘的自行愈合,联合肠内营养与外科引流有助于促进肠瘘自行愈合。同时要重视围手术期营养状况的评估,并给予营养支持治疗。合并的腹腔脓肿建议使用Trocar穿刺置双套管建立主动冲洗引流.药物、营养治疗以及外科, cover=, journalId=null, articlesId=null, associationId=737, associationName=中国医师协会外科医师分会, associationIntro=null, copyright=0, guiderPublishedTime=Sun Dec 30 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>克罗恩病是累及消化道全层的慢性炎性疾病,肠瘘是其最为严重的外科并发症。治疗目标是治愈肠瘘与腹腔感染、恢复消化道的连续性、减少术后复发和改善生活质量。临床上应对克罗恩病并发的肠瘘进行充分评估,努力促进肠瘘的自行愈合,联合肠内营养与外科引流有助于促进肠瘘自行愈合。同时要重视围手术期营养状况的评估,并给予营养支持治疗。合并的腹腔脓肿建议使用Trocar穿刺置双套管建立主动冲洗引流.药物、营养治疗以及外科引流未能治愈的克罗恩病并发的肠外瘘与肠内瘘,需要考虑手术治疗,推荐腹腔镜手术应用于粘连较轻的克罗恩病并发的肠瘘,术后予以药物治疗并定期复查,尽可能减少克罗恩病术后复发以及肠瘘的再发。 </div> <div><br> </div>拓展指南:<strong>与<font color=red>克罗恩病</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=462c61c001688130" title="2019 SNFCP国家共识:克罗恩病肛门会阴病变的管理" target=_blank>2019 SNFCP国家共识:克罗恩病肛门会阴病变的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=7af621c00162837c" title="2018 多伦多共识:肛周瘘管性克罗恩病的医学管理指南" target=_blank>2018 多伦多共识:肛周瘘管性克罗恩病的医学管理指南</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=217bf1c00160e225" title="2018 多学科专家共识:克罗恩病抗纤维化狭窄治疗的标准化定义,诊断和治疗目标" target=_blank>2018 多学科专家共识:克罗恩病抗纤维化狭窄治疗的标准化定义,诊断和治疗目标</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=fccaa1c0015e71b8" title="2018 ACG临床指南:成人克罗恩病的管理" target=_blank>2018 ACG临床指南:成人克罗恩病的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=8d9001c001a6e962" title="2017 台湾克罗恩病管理指南" target=_blank>2017 台湾克罗恩病管理指南</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E5%85%8B%E7%BD%97%E6%81%A9%E7%97%85" target=_blank>有关克罗恩病更多指南</a></ul>, tagList=[TagDto(tagId=984, tagName=克罗恩病), TagDto(tagId=18442, tagName=肠瘘)], categoryList=[CategoryDto(categoryId=4, categoryName=消化, tenant=100), CategoryDto(categoryId=76, categoryName=胃肠外科, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=10660, appHits=382, showAppHits=0, pcHits=8401, showPcHits=2903, likes=260, shares=17, comments=3, approvalStatus=1, publishedTime=Mon Jan 21 23:45:44 CST 2019, publishedTimeString=2018-12-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Jan 21 23:45:44 CST 2019, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 08:01:41 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=中国克罗恩病并发肠瘘诊治的专家共识意见)])
中国克罗恩病并发肠瘘诊治的专家共识意见
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1184811, encodeId=1c5f11848112f, content=棒棒哒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da04961876, createdName=243258547, createdTime=Sun Jan 16 12:36:26 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184810, encodeId=f65c118481059, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da04961876, createdName=243258547, createdTime=Sun Jan 16 12:36:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361450, encodeId=36a73614501a, content=实用好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2431968, createdName=123ba698m96暂无昵称, createdTime=Mon Feb 25 07:12:52 CST 2019, time=2019-02-25, status=1, ipAttribution=)]
    2022-01-16 243258547

    棒棒哒

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1184811, encodeId=1c5f11848112f, content=棒棒哒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da04961876, createdName=243258547, createdTime=Sun Jan 16 12:36:26 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184810, encodeId=f65c118481059, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da04961876, createdName=243258547, createdTime=Sun Jan 16 12:36:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361450, encodeId=36a73614501a, content=实用好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2431968, createdName=123ba698m96暂无昵称, createdTime=Mon Feb 25 07:12:52 CST 2019, time=2019-02-25, status=1, ipAttribution=)]
    2022-01-16 243258547

    好文

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1184811, encodeId=1c5f11848112f, content=棒棒哒, beContent=null, objectType=guider, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da04961876, createdName=243258547, createdTime=Sun Jan 16 12:36:26 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1184810, encodeId=f65c118481059, content=好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=2da04961876, createdName=243258547, createdTime=Sun Jan 16 12:36:04 CST 2022, time=2022-01-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=361450, encodeId=36a73614501a, content=实用好文, beContent=null, objectType=guider, channel=null, level=null, likeNumber=82, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=cd5c2431968, createdName=123ba698m96暂无昵称, createdTime=Mon Feb 25 07:12:52 CST 2019, time=2019-02-25, status=1, ipAttribution=)]
    2019-02-25 123ba698m96暂无昵称

    实用好文

    0